With the goal of suggesting dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN), herein we report the molecular docking of an initial set of 556 compounds related to the pyridinone class. Docking with multiple crystallographic structures of HIV-1 RT led to 160 potential binders of RT interacting with key amino acid residues at the enzyme's allosteric site. Compounds selected from the docking with RT were further docked with a crystallographic structure of HIV-1 IN. A total of 31 structures had the potential to make contacts with Mg 2+ ions located in a small space between DNA and IN. Interactions with Mg 2+ ions are relevant because they participate in the stabilization of the IN-DNA complex. In conclusion, 31 compounds synthetically accessible are proposed as dual inhibitors of RT and IN. It is hypothesized that the suggested compounds will inhibit RT by occupying the allosteric site for NNRTIs and will inhibit the catalytic activity of IN by destabilizing the IN-DNA complex. The main perspective of this work is the synthesis and biological testing of the candidate molecules.
Introduction
Acquired Immune Deficiency Syndrome (AIDS) continues to be a major health problem in the world. In 2016, there were 1.0 million AIDS-related deaths and 36.7 million people living with the human immunodeficiency virus (HIV) [1] . Computational Molecular Bioscience Several compounds have been developed for the treatment of patients infected with HIV-1 [2] - [7] . These compounds, based on the mechanism of action, can be classified into five major groups: CCR5 blockers, fusion inhibitors, reverse transcriptase (RT) inhibitors (that include nucleoside, NRTIs and nonnucleoside, NNRTIs), integrase (IN), and protease (PI) inhibitors [8] . The molecular targets are involved in different aspects of the HIV virus. For instance, RT is responsible for producing proviral DNA from viral RNA, and IN is responsible for taking the proviral DNA and introducing it to cellular DNA in the nucleus [8] [9]. HIV infection is currently controlled through combinations of drugs described above, collectively known as the Highly Active Antiretroviral Therapy (HAART). In this polypharmacy approach [11] , the FDA has approved for clinical use multiclass combination products that contain PI or NRTI combined [12] .
On the other hand, a polypharmacology approach [11] , attempts to develop dual active compounds such as 11 -18 ( Figure 1 ) that inhibit both RT and IN [6] .
Since the induction of adverse side effects and the emergence of drug-resistant strains of HIV are major challenges of anti-HIV therapies, the development of multi-target drugs is an alternative to increase antiviral activity and to reduce the number of components in the combinations currently used [11] .
Pyridinone derivatives are promising NNRTIs. [15] . Amongst these compounds are pyrimidinediones [16] , which contain an OH group in N-1 of the pyridione ring and that were proposed as dual inhibitors of RT and IN (Figure 1 ) [6] .
The goal of this work was to assess the potential ability of pyridinone analogues and related compounds to act as dual inhibitors of RT and IN. The rationale is that dual inhibitors may be more effective than molecules directed to only one molecular target [17] . The rationale is that the proposed pyridinone derivatives (cf. Figure 2 ) are structurally related to the 3-hydroxypyrimidine-2,4-diones that are dual inhibitors of RT and IN as showed by Wang et al. All the compounds evaluated in this study (cf. Figure 2 ) are synthetically accessible. As discussed in section 2, the designed structures have features of the pyridinone-UC781 hybrid, that might maintain activity against mutant strains [4] . In Figure 2 . Chemical structures of the pyrdinone derivatives considered in this work. 
Methods
Based on the structure of the pyridinone-UC781 hybrid proposed earlier [4] , chemical structure of 556 compounds was initially proposed based on synthetic accessibility ( Figure 2 ). The overall rationale of the design was to introduce a polar group at C-3 and an unsaturated aliphatic chain in C-4. The chemical structures of the 3-hydroxypyrimidine-2,4-diones developed by Wang et al. were also considered in the design. In particular, the introduction of an N-OH substitution would lead to candidate compounds able to act as dual inhibitors, inhibiting both RT and IN [6] .
The crystallographic structures of the biomolecular targets were retrieved from the Protein Data Bank (PDB) (www.rcsb.org) [18] . Table 1 
Validation of Docking Protocol
Before docking the new compounds in Figure 2 , the docking protocol was validated by re-docking the co-crystal ligands in their corresponding crystallographic structure (Table 1) . During docking, the structure of the co-crystal ligands (i.e., R221239, R165481, R157208 and GS9137) was considered semi-flexible.
The docking was done with the MMFF94x force field using default options of MOE (500 iterations in total with 30 consecutive attempts to select the best result). The binding pocket was defined as the set of amino acids within of 4.5 Å of the co-crystal ligand.
3D Flexible Alignment of Pyridinone Structures
In order to explore if the compounds in Figure 2 could adopt a similar conformation as the co-crystalized pyridinone analogues, a representative set of 56 (10%) molecules were aligned flexibly to the co-crystal coordinates of R221239, R165481, and R157208 ( Table 1 ). The chemical structures of the 56 selected compounds are in the Supplementary material. During the alignment, the structure of the co-crystal compound was kept rigid. The flexible alignment conducted in MOE was done using default settings (500 iterations in total with 30 consecutive attempts to find the best result) with the MMFF94x force field.
Docking

Docking with RT
All 556 compounds were docked with the crystallographic structures PDB ID:
2BAN and 2B5J using the same settings of the validation step. After docking with the two crystallographic structures, 160 compounds were selected for further analysis. As part of the analysis, in particular the binding poses, protein ligand interaction fingerprints (PLIFs) were generated with MOE. Of note, the Figure 2 were not docked with PDB ID: 2BE2 based on the results of the flexible alignment detailed in Section 2.3 i.e., the proposed compounds did not adopted a similar conformation to R221239 (vide infra). 
Docking with IN
Calculation of Drug-Like Properties
In order to assess the potential oral bioavailability of the newly proposed compounds, we calculated properties of pharmaceutical interest, namely [21] [22]; molecular weight (MW), the partition coefficient octanol/water (Log P) as a measure of lipophilicity, topological polar surface area (TPSA), number of hydrogen bond donors (HBD), hydrogen bond acceptors (HBA), and rotatable bonds (RB).
Results and Discussion
Alignment of Crystallographic Structures of RT
The three crystallographic structures of RT (Table 1) were aligned before the docking. Figure 
Validation of the Docking Protocol with RT
Alignment with Co-Crystalized Pyridinone Derivatives
As described in the Methods section, 56 (10%) pyridinones were taken from the entire set of 556 molecules using a stratified random sampling strategy ( Figure   S6 in the Supplementary material). The selected structures were aligned flexibly with the co-crystallographic positions of R157208, R165481 and R221239 (Table   1) . Table 2 summarizes the results of the 3D alignment including the scores.
This value quantifies the quality of the alignment taking into account the 3D similarity of the molecules considering the average energy penalty (in kcal/mol) for the conformational restriction of the ligands associated with the alignment.
Lower values (more negative) indicate a better alignment. The colors of the alignment values in Table 2 classify the relative magnitude of the alignment scores as compared to the average plus two standard deviations of the scores vs. the Supplementary material ( Figure S5 ). Table 3 and Table 4 summarize the docking scores of the selected compounds with two crystal structures of RT. The more negative values indicate more favorable docking. Table 3 shows the results with PDB ID: 2BAN and Table 4 with PDB ID: 2B5J. In both tables, compounds in the left column are the ones able to make contacts with Tyr181-Tyr188 and those on the right column make contact with Trp-Pro236 or Trp229-Pro236-Tyr318, respectively.
Docking with RT
Based on the results of the 3D flexible alignment discussed in section 3.3, the structure PDB ID: 2BE2 structure was no longer considered for docking analysis.
As discussed, this was because the results suggested that the geometry of the binding site of R221239 bound to RT is not representative for the group of compounds studied in this work. 
Binding Modes with RT, PDB ID: 2BAN
Based on the docking scores and predicted contacts with key amino acids ( Figure S7 ) (PDF file "160 structures docked with RT"). . Both binding models is predicted the characteristic hydrogen bond with Lys101. In addition, the substituent at C-4 (4-methylpent-3-en-1-oxyde) is flexible and can make contacts with Tyr181, Tyr188, Trp229, Pro236 or Tyr318. Such flexibility is important in mutant strains because the group in C-4 will help the compound to maintain the interaction with other amino acid in the allosteric site and in this way would favor activity against mutant RT [4] . Figure 6 illustrates a further example of this flexibility of the C-4 position (R4 substituent). In this binding model, compound 447 makes two hydrogen bond interactions with Lys101 and Lys103. At the same time, the molecule has the potential to interact with the side chains of Tyr188 or Trp229 Through the substituent at C-4. Table 4 other amino acid residues in the pocket. In all cases, compounds make a hydrogen bond interaction with Lys101.
Binding Modes with RT, PDB ID: 2B5J
For example, compound 315 had a favorable docking score and also was able to make hydrophobic contacts with Tyr181 (Table 4 ). score of -8.83) that is predicted to have contacts with Trp229 (Table 4 ). This compound can make hydrogen bond interactions with Lys101 and make contacts with Leu100. 
Validation of the Docking Protocol with IN
The docking protocol with IN was validated by re-docking the co-crystal ligand Elvitegravir. The RMSD value of 1.3 Å indicated the ability of the docking protocol to reproduce the binding mode observed in the co-crystallized structure (see Figure S3 in the Supplementary material).
Docking with IN
A total of 76 compounds that had good docking results with RT (vide supra) were docked with IN. Of note, structures of compounds selected had ester and acid groups in C-3 ( Figure 2 ) and, overall, similar functional groups as known IN inhibitors. Table 5 Table 3 and Table 4 , compounds in Table 5 Molecule 54 had the most favorable docking score. Figure 10 shows its binding model. Notably, 54 can make interactions with two Mg 2+ atoms, similar to
Elvitegravir. Based on this result, it is hypothesized that 54 and other molecules with favorable docking scores (Table 5) could be IN inhibitors.
Potential Dual Inhibitors of RT and IN
Taken together the results of the docking with RT and IN, it was concluded that 31 molecules could act as dual inhibitors. Figure 11 shows the chemical structures of the seven structures of the newly designed compounds with the best docking results (e.g., docking poses and scoring) obtained with both, RT and IN.
As determined with the PDB ID: 2BAN and 2B5J RT structures, the compounds can make protein-ligand contacts with key amino acids for activity against native and mutant strains. In addition, the same seven structures are able to interact with the Mg 2+ ions in the cavity between the enzyme and DNA, similar to the reports of the IN inhibitors.
Drug-Like Properties
The with the rules of Lipinski and Veber (Table S1 and Figure S4 in the Supplementary material).
Conclusions and Perspectives
Using automated molecular docking with multiple crystallographic structures of Figure S4 . Distribution of the drug-like properties of newly designed compounds (see also Table S1 ). For the docking results with PDB ID: 2B5J it was generated a list using data of PLIF where was selected the Lys101 backbone donor interaction ( Figure S5B ).
Analysis of PLIFS
The list of conformations that implied Lys101 had 2,157 conformations from a total of 13,548 conformations. As next step 2157 posed were analyzed obtaining 91 structures with interaction with Tyr181, Tyr188, Trp229, Pro236 and Tyr318.
PLIF of docking results with IN (PDB: 3L2U)
Once we selected 76 structures with similar structural characteristics to Elvitegravir and performed the docking, PLIFs were generated with MOE. The goal was to identify those compounds with similar interactions as the reference co-crystal ligand, Elvitegravir, in particular the interactions with Mg 2+ ions. The docking simulations gave 1862 conformations and was generated the PLIF in MOE. The data of PLIF were organized to get a list of conformations that interact with two Mg 2+ and where listed 187 conformations of compounds that had interaction at the same time with two atoms of Mg 2+ ( Figure S5C ).
